<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04262687</url>
  </required_header>
  <id_info>
    <org_study_id>FFCD 1703 POCHI</org_study_id>
    <nct_id>NCT04262687</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate</brief_title>
  <acronym>POCHI</acronym>
  <official_title>Pembrolizumab in Combination With Xelox Bevacizumab in Patients With Microsatellite Stable Mestatic Colorectal Cancer and a High Immune Infiltrate : a Proof of Concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federation Francophone de Cancerologie Digestive</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      About 85% of cases of non-metastatic colorectal cancer (CRC) are related to chromosomal
      instability and have a proficient DNA Mismatch-Repair system (pMMR); which are also called
      CRC with microsatellite stability (MSS). Other CRC, i.e. 15%, are &quot;microsatellite unstable&quot;
      (MSI) with deficient DNA Mismatch-Repair system (dMMR). These latter are characterised by
      generation of many neo-antigens, which result in a high anti-tumour immune response and a
      high peri- and/or intra-tumour lymphocyte infiltration (TIL). Investigators recently showed,
      with a prospectively validated immune score, that 14% of localised MSS/pMMR CRC are also
      highly infiltrated by CD3+ lymphocytes. This same immune score has made it possible to
      measure high lymphocyte infiltration in hepatic metastases, in particular, in patients
      treated with XELOX/FOLFOX.

      Pembrolizumab, an anti-PD1 monoclonal antibody (programmed death-1) is an immune checkpoint
      inhibitor (ICI) of PD1/PD-L1 axis, recently approved in many cancers. Anti-PD1 antibodies
      have recently been reported as being very effective in patients with dMMR metastatic CRC
      (mCRC). In the study by Le DT et al. pMMR mCRC did not seem to benefit from anti-PD1
      antibodies. However, it is possible that 20% of pMMR mCRC with a high CD3+ infiltrate in the
      tumour may be a subgroup of pMMR mCRC sensitive to ICI, as is the case for dMMR mCRC. Lastly,
      immunogenic cell death induced by chemotherapy, such as oxaliplatin, can increase the
      efficacy of ICI.

      The prognostic value of lymphocyte infiltrate has been demonstrated in CRC by several teams.
      However, no validated test is used in routine clinical practice. Previously, investigators
      described an automated and reproducible method for analysis of TIL and investigators
      validated it for clinical use. Automated tests evaluating TIL are performed on virtual slides
      and have showed that, out of 1,220 tumours tested, 20% were highly infiltrated by CD3+ T
      cells. Patients presenting with a pMMR CRC with a high immune infiltrate had a better
      progression-free survival (HR=0.70; p=0.02). An immunoscore® described by Galon et al. has
      also a high prognostic value in CRC and is based on CD3+ and CD8+ T cells infiltration in the
      center and periphery of the tumour. Finally, approximately 14% of tumours with a high immune
      infiltrate have been found in patients with metastatic CRC.

      Investigators formulated the hypothesis that patients with a pMMR CRC with a high immune
      infiltrate can be sensitive to ICI . Therefore, blocks of resected primary tumour will be
      collected and analysed prospectively. For each patient, slides containing tumour tissue and
      adjacent non-tumour tissue will be analysed using immunohistochemistry with CD3 and CD8
      staining. Slides will be scanned and analysed by image analysis as previously described .
      Tumours will then be classified as having a &quot;high&quot; or &quot;low&quot; immune response according to type
      of lymphocyte infiltrate, which is independent of pre-analytic conditions. Only patients with
      a high immune response will be eligible for the POCHI trial. Other biomarkers will be
      analysed like other immune populations or mutational load. If investigators identify an
      immune score which seems clinically relevant to predict sensitivity to ICI in pMMR mCRC, this
      will make it possible to plan a randomised phase III trial comparing chemotherapy and
      anti-angiogenic antibody versus chemotherapy and anti-angiogenic antibody plus pembrolizumab
      in patients with a pMMR mCRC with a high immune score and/or a hypermutated genotype.

      Investigators choose PFS at 10 months as primary endpoint in POCHI trial because it is a
      surrogate marker of OS. Actually median PFS in first-line setting with a doublet plus a
      biological agent is range from 8 to 11 months in unresectable mCRC, corresponding to a PFS of
      50% at 10 months. The alternative clinical hypothesis to obtain 70% of patients alive and
      without progression at 10 months is ambitious and currently not achieved with current
      chemotherapies plus a biological agent. Up until now there is no data concerning survivals
      outcomes of patients with a MSS mCRC with high immune infiltration score.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the efficacy of pembrolizumab in combination with XELOX and bevacizumab as 1st line treatment of microsatellite stable (MSS) metastatic colorectal cancer (mCRC) with a high immune infiltrate</measure>
    <time_frame>From date of inclusion until 10 months after inclusion</time_frame>
    <description>the percentage of patients alive and without progression at 10 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>through study completion, an average of 2 year</time_frame>
    <description>date of death of patient (whatever the cause) or date of last news if patient is alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events evaluated according to NCI-CTC v4.0</measure>
    <time_frame>total duration of treatment and 30 days after treatment</time_frame>
    <description>Evaluated according to NCI-CTC v4.0 criteria and described by maximum grade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological response in case of secondary resection</measure>
    <time_frame>through study completion, an average of 2 year</time_frame>
    <description>evaluated according to the TRG (Rubbia-Brandt L et al. Annals Oncol 2007), in patients who underwent a secondary resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome of tumour markers</measure>
    <time_frame>through study completion, an average of 2 year</time_frame>
    <description>CEA and CA19.9: the evolution of the markers will be analyzed by a graphic representation of the percentage change from baseline rate.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <condition>High Immune Infiltrate</condition>
  <condition>Microsatellite Stable</condition>
  <arm_group>
    <arm_group_label>Immunotherapy + chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xelox bevacizumab plus pembrolizumab every 3 weeks up until disease progression, unacceptable toxicity, refusal by the patient, withdrawal of consent, pregnancy or decision by the investigator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>2000 mg/m²/day, from day 1 to 14 of each cycle</description>
    <arm_group_label>Immunotherapy + chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>130 mg/m² by IV infusion over 2 hours, on day 1 of each cycle</description>
    <arm_group_label>Immunotherapy + chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>7.5 mg/kg by IV infusion over 60 minutes, on day 1 of each cycle</description>
    <arm_group_label>Immunotherapy + chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>200 mg by IV infusion over 30 minutes, on day 1 of each cycle</description>
    <arm_group_label>Immunotherapy + chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  MSS and pMMR metastatic colorectal adenocarcinoma (metachronous or synchronous
             metastases), histologically proven

          -  Patients who have had chemotherapy (neo-adjuvant or adjuvant) or radiotherapy
             (neo-adjuvant or adjuvant) for the treatment of primary tumor or metastatic resected
             disease R0 can be included if they have a recurrence more than 6 months after the end
             of this treatment.

          -  High immune response defined as the immune infiltration scores obtained on the primary
             tumour (resection of primary tumour containing at least 2 mm of tumour-free margin
             between the tumour and non-tumour area)

          -  Unresectable cancer with at least one measurable metastatic target according to RECIST
             v1.1 criteria

          -  WHO PS ≤ 1

          -  Life expectancy ≥ 3 months

          -  Adequate haematological function: neutrophils ≥ 1,500 /mm3, platelets ≥ 100,000/mm3,
             Hb &gt; 9 g/dL

          -  Adequate liver function: AST/ALT ≤ 5xULN, total bilirubin ≤ 2xULN, alkaline
             phosphatase. ≤ 5xULN

          -  Creatinine clearance &gt; 50 mL/min according to the MDRD formula

          -  Proteinuria &lt;2+ (dipstick urinalysis) or ≤1g/24hour

          -  Patient who is a beneficiary of the social security system

          -  Information provided to patient and signature of the informed consent form

        Exclusion Criteria:

          -  Active infection requiring intravenous antibiotics at day 1 of cycle 1

          -  Active or untreated central nervous system metastases

          -  Another concomitant cancer or history of cancer during the last 5 years, except for
             carcinoma in situ of the uterine cervix or a basal cell or squamous cell skin
             carcinoma or any other carcinoma in situ considered as cured

          -  Previous bone marrow allogenic stem cell transplantation or previous organ
             transplantation

          -  History of idiopathic pulmonary fibrosis, medicinal product-related pneumonia or proof
             of active pneumonia or pneumonitis on a chest CT-scan prior to therapy

          -  HIV infection, active hepatitis B or C infection, active tuberculosis

          -  Colorectal cancer with microsatellite instability (dMMR and/or MSI)

          -  Patient eligible for curative treatment (resection and/or thermal ablation according
             to the opinion of the local multidisciplinary tumour meeting board)

          -  Patient with only primary tumour biopsies available or only a sample of a metastasis
             (no surgical resection of the primary tumour)

          -  Previous treatment with anti-PD1 or anti-PDL1 or another immunotherapy

          -  An auto-immune disease which may worsen during treatment with an immune-stimulating
             agent (patients with type I diabetes, vitiligo, psoriasis, hypo or hyperthyroidism not
             requiring immunosuppressant therapy are eligible)

          -  Long-term immunosuppressant therapy (patients requiring corticosteroid therapy are
             eligible if administration at a dose ≤ 10 mg prednisone equivalent dose per day,
             administration of steroids by a route of administration resulting in minimal systemic
             exposure (cutaneous, rectal, ocular or inhalation) is authorised)

          -  Known severe hypersensitivity to monoclonal antibodies, to one of the medicinal
             products used or to one of the excipients in the products used or a history of
             anaphylactic shock or of uncontrolled asthma

          -  Vaccinations (live vaccine) within 30 days prior to start of treatment

          -  Dihydropyrimidine Dehydrogenase (DPD) deficiency defined by uracilemy level ≥ 16 ng/mL

          -  QT/QTc interval &gt; 450 msec in men and &gt; 470 msec in women

          -  One of the following disorders during the 6 months prior to inclusion: myocardial
             infarction, unstable/severe angina pectoris, coronary artery bypass grafting, NYHA
             class II, III or IV congestive heart failure, stroke or transient ischaemic attack

          -  All uncontrolled progressive disorders during the last 6 months: hepatic
             insufficiency, renal insufficiency, respiratory insufficiency, arterial hypertension

          -  History of an inflammatory digestive disease, obstruction or sub-obstruction not
             resolved with symptomatic treatment

          -  Peptic ulcer disease not healed before the treatment

          -  Not controlled HTA

          -  Patient already enrolled in another therapeutic trial with an ongoing investigational
             drug or whose treatment ended less than 4 weeks before inclusion

          -  Absence of effective contraception in patients (male and/or female patients) of
             childbearing potential, a pregnant or breastfeeding woman, women of childbearing
             potential and who have not had a pregnancy test

          -  Impossibility to submit to medical follow-up of the trial due to geographic, social or
             psychological reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David TOUGERON, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU POITIERS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeremie BEZ</last_name>
    <phone>0380393483</phone>
    <email>jeremie.bez@u-bourgogne.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier d'Abbeville</name>
      <address>
        <city>Abbeville</city>
        <zip>80090</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mathieu Pauwels, Dr</last_name>
      <phone>+33 3 22 25 53 10</phone>
      <email>pauwels.mathieu@ch-abbeville.fr</email>
    </contact>
    <investigator>
      <last_name>Mathieu Pauwels, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Amiens-Picardie</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Vincent HAUTEFEUILLE, Dr</last_name>
      <phone>+33 3 22 08 88 49</phone>
      <email>hautefeuille.vincent@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent HAUTEFEUILLE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ico - Site Paul Papin - Angers</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Judith RAIMBOURG, Dr</last_name>
      <phone>+33 2 40 67 98 21</phone>
      <email>judith.raimbourg@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Judith RAIMBOURG, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé - Pays de Savoie</name>
      <address>
        <city>Annemasse</city>
        <zip>74100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Wulfran CACHEUX, Dr</last_name>
      <phone>+33 4 50 83 42 38</phone>
      <email>w.cacheux@ramsaygds.fr</email>
    </contact>
    <investigator>
      <last_name>Wulfran CACHEUX, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Prive D'Antony</name>
      <address>
        <city>Antony</city>
        <zip>92160</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne THIROT BIDAULT, Dr</last_name>
      <phone>+33 1 46 74 41 73</phone>
      <email>a.t.bidault@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Anne THIROT BIDAULT, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Henri Duffaut</name>
      <address>
        <city>Avignon</city>
        <zip>84902</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Thibault BROTELLE, Dr</last_name>
      <phone>+33 4 32 75 93 30</phone>
      <email>brotelle.thibault@ch-avignon.fr</email>
    </contact>
    <investigator>
      <last_name>Thibault BROTELLE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ch Cote Basque</name>
      <address>
        <city>Bayonne CEDEX</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Franck AUDEMAR, Dr</last_name>
      <phone>+33 5 59 44 37 22</phone>
      <email>faudemar@ch-cotebasque.fr</email>
    </contact>
    <investigator>
      <last_name>Franck AUDEMAR, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ch de Beauvais</name>
      <address>
        <city>Beauvais</city>
        <zip>60021</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Fayçal HOCINE, Dr</last_name>
      <phone>+33 3 44 11 23 09</phone>
      <email>f.hocine@ch-beauvais.fr ; fayoncologie@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Fayçal HOCINE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Stéfano KIM, Dr</last_name>
      <phone>+33 3 81 98 87 75</phone>
      <email>alrollin@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Stéfano KIM, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique de Bordeaux Nord</name>
      <address>
        <city>Bordeaux CEDEX</city>
        <zip>33077</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Cédric LECAILLE, Dr</last_name>
      <phone>+33 5 56 69 06 81</phone>
      <email>lecail@hotmail.com; m.balhadere@hotmail.fr</email>
    </contact>
    <investigator>
      <last_name>Cédric LECAILLE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié BORDEAUX</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Simon PERNOT, Dr</last_name>
      <phone>+33 5 56 33 04 00</phone>
      <email>simon.pernot@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Simon PERNOT, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Morvan Institut de cancérologie</name>
      <address>
        <city>Brest Cedex 2</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre Guillaume POUREAU, Dr</last_name>
      <phone>+33 2 98 03 80 30</phone>
      <email>pierre-guillaume.poureau@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Guillaume POUREAU, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Maurice Tubiana</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Emmanuel SEVIN, Dr</last_name>
      <phone>+33 2 31 82 84 62</phone>
      <email>e.sevin@i-l-c.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuel SEVIN, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Stéphane CORBINAIS, Dr</last_name>
      <phone>+33 2 31 45 40 20</phone>
      <email>s.corbinais@baclesse.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane CORBINAIS, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infirmerie Protestante de Lyon</name>
      <address>
        <city>Caluire-et-Cuire</city>
        <zip>69300</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Johannes HARTWIG, Dr</last_name>
      <phone>+33 4 72 00 71 67</phone>
      <email>johannes.hartwig@infirmerie-protestante.com</email>
    </contact>
    <investigator>
      <last_name>Johannes HARTWIG, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Médipole de Savoie</name>
      <address>
        <city>Challes-les-Eaux</city>
        <zip>73190</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Christine REBISCHUNG, Dr</last_name>
      <phone>+33 4 79 26 80 61</phone>
      <email>c.rebischung@medipole-de-savoie.fr</email>
    </contact>
    <investigator>
      <last_name>Christine REBISCHUNG, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Prive Paul D'Egine</name>
      <address>
        <city>Champigny-sur-Marne</city>
        <zip>94500</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Adil CHAFAI EL ALAOUI, Dr</last_name>
      <phone>+33 1 49 83 64 05</phone>
      <email>adil.alaoui@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Adil CHAFAI EL ALAOUI, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chauny Centre Hospitalier</name>
      <address>
        <city>Chauny</city>
        <zip>02303</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marc KANAAN, Dr</last_name>
      <phone>+33 3 23 38 46 42</phone>
      <email>marc.kanaan@ch-chauny.fr</email>
    </contact>
    <investigator>
      <last_name>Marc KANAAN, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de CHOLET</name>
      <address>
        <city>Cholet</city>
        <zip>49300</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>You-Heng LAM, Dr</last_name>
      <phone>06 31 62 39 72</phone>
      <email>you-heng.lam@ch-cholet.fr</email>
    </contact>
    <contact_backup>
      <phone>02 41 49 66 79</phone>
    </contact_backup>
    <investigator>
      <last_name>You-Heng LAM, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU d'Estaing CLERMONT FERRAND</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Caroline PETORIN</last_name>
      <phone>+33 4 73 75 05 08</phone>
      <email>cpetorin@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Caroline PETORIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopitaux Civils de Colmar</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Gilles BREYSACHER, Dr</last_name>
      <phone>+33 3 89 12 51 23</phone>
      <email>gilles.breysacher@ch-colmar.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles BREYSACHER, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Come</name>
      <address>
        <city>Compiègne CEDEX</city>
        <zip>60204</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Kaïs ALDABBAGH, Dr</last_name>
      <phone>+33 3 44 92 43 53</phone>
      <email>kais.aldabbagh@stcome.com</email>
    </contact>
    <investigator>
      <last_name>Kaïs ALDABBAGH, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique de Flandre</name>
      <address>
        <city>Coudekerque-Branche</city>
        <zip>59210</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurence CHOSSIERE, Dr</last_name>
      <phone>+33 3 28 28 14 39</phone>
      <email>jpwagner@onco-institut-adutreix.org ; jpwagner@iadonco.org</email>
    </contact>
    <investigator>
      <last_name>Laurence CHOSSIERE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GHPSO Site de Creil</name>
      <address>
        <city>Creil</city>
        <zip>60100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Elisabeth CAROLA, Dr</last_name>
      <phone>03 44 61 63 03</phone>
      <email>elisabeth.carola@ghpso.fr</email>
    </contact>
    <investigator>
      <last_name>Elisabeth CAROLA, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil CEDEX</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Isabelle BAUMGAERTNER, Dr</last_name>
      <phone>+33 1 49 81 25 76</phone>
      <email>isabelle.baumgaertner@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle BAUMGAERTNER, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Francois Mitterrand</name>
      <address>
        <city>Dijon CEDEX</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sylvain MANFREDI, Pr</last_name>
      <phone>+33 3 80 29 37 50</phone>
      <email>sylvain.manfredi@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvain MANFREDI, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>François GHIRINGHELLI, Pr</last_name>
      <phone>+33 3 80 73 75 28</phone>
      <email>fghiringhelli@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>François GHIRINGHELLI, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU GRENOBLE ALPES - Hôpital Albert Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Gaël ROTH, Dr</last_name>
      <phone>+33 4 76 76 51 68</phone>
      <email>groth@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Gaël ROTH, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique de Blois - 3Eme Etage</name>
      <address>
        <city>La Chaussee St Victor</city>
        <zip>41260</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Philippe LAPLAIGE, Dr</last_name>
      <phone>+33 2 54 90 65 57</phone>
      <email>dr.laplaige@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe LAPLAIGE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHD Vendée - La Roche-sur-Yon</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Margot LALY, Dr</last_name>
      <phone>+33 2 51 44 61 68</phone>
      <email>margot.laly@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Margot LALY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Dupuytren - Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Valerie LE BRUN LY, Dr</last_name>
      <phone>+33 5 55 05 63 96</phone>
      <email>valerie.ly@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Valerie LE BRUN LY, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Du Scorff - Chbs</name>
      <address>
        <city>Lorient CEDEX</city>
        <zip>56322</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Joëlle EGRETEAU, Dr</last_name>
      <phone>+33 2 97 06 96 94</phone>
      <email>j.egreteau@ghbs.bzh</email>
    </contact>
    <investigator>
      <last_name>Joëlle EGRETEAU, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Prive Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Chloé VERNET, Dr</last_name>
      <phone>+33 4 37 53 87 26</phone>
      <email>chloe.vernet2@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chloé VERNET, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Lyon Sud - Pierre Benite</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marion CHAUVENET, Dr</last_name>
      <phone>+33 4 78 86 13 02</phone>
      <email>marion.chauvenet@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Marion CHAUVENET, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Marseille</name>
      <address>
        <city>Marseille CEDEX 03</city>
        <zip>13331</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Yves RINALDI, Dr</last_name>
      <phone>+33 4 13 42 77 13</phone>
      <email>y.rinaldi@hopital-europeen.fr; yrinaldi@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Yves RINALDI, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu La Timone</name>
      <address>
        <city>Marseille CEDEX 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laétitia DAHAN, Pr</last_name>
      <phone>+33 4 91 38 60 23</phone>
      <email>laetitia.dahan@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Laétitia DAHAN, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Joseph</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>HERVE PERRIER, Dr</last_name>
      <phone>+33 4 91 80 82 11</phone>
      <email>hperrier@hopital-saint-joseph.fr</email>
    </contact>
    <investigator>
      <last_name>HERVE PERRIER, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier de l'Est Francilien - MEAUX</name>
      <address>
        <city>Meaux</city>
        <zip>77100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Christophe LOCHER, Dr</last_name>
      <phone>+33 1 64 35 12 64</phone>
      <email>c-locher@ch-meaux.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe LOCHER, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HOPITAL LAYNE - CH de MONT DE MARSAN</name>
      <address>
        <city>Mont-de-Marsan</city>
        <zip>40 000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Patrick TEXEREAU, Dr</last_name>
      <phone>+33 5 58 05 11 66</phone>
      <email>patrick.texereau@ch-mdm.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick TEXEREAU, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Azureen de Cancerologie</name>
      <address>
        <city>Mougins</city>
        <zip>06250</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Benjamin HOCH, Dr</last_name>
      <phone>+33 4 92 92 37 85</phone>
      <email>dr.bhoch@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Benjamin HOCH, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Prive Arnault Tzanck</name>
      <address>
        <city>Mougins</city>
        <zip>06250</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Benjamin HOCH, Dr</last_name>
      <phone>+33 4 92 92 37 37</phone>
      <email>dr.bhoch@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Benjamin HOCH, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique de Gentilly</name>
      <address>
        <city>Nancy</city>
        <zip>54100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Fabien BROCARD, Dr</last_name>
      <phone>+33 3 83 93 50 05</phone>
      <email>f.brocard@oncog.fr</email>
    </contact>
    <investigator>
      <last_name>Fabien BROCARD, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Carémeau</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Valérie PHOUTTHASANG, Dr</last_name>
      <phone>+33 4 66 68 31 83</phone>
      <email>Valivalo@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Valérie PHOUTTHASANG, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Christophe LOUVET, Dr</last_name>
      <phone>+33 1 56 61 60 35</phone>
      <email>christophe.louvet@imm.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe LOUVET, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Julien TAIEB, Dr</last_name>
      <phone>+33 1 56 09 35 56</phone>
      <email>jtaieb75@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Julien TAIEB, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Diaconesses Croix Saint Simon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Olivier DUBREUIL, Dr</last_name>
      <phone>+33 1 44 74 28 39</phone>
      <email>ODubreuil@hopital-dcss.org</email>
    </contact>
    <investigator>
      <last_name>Olivier DUBREUIL, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CENTRE HOSPITALIER de PAU</name>
      <address>
        <city>Pau CEDEX</city>
        <zip>64046</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Juliette THAURY, Dr</last_name>
      <phone>+33 5 59 92 49 83</phone>
      <email>juliette.thaury@ch-pau.fr</email>
    </contact>
    <investigator>
      <last_name>Juliette THAURY, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique FRANCHEVILLE</name>
      <address>
        <city>Perigueux</city>
        <zip>24004</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurent CANY, Dr</last_name>
      <phone>+33 5 53 02 13 32</phone>
      <email>I.cany@oncoradio24.com</email>
    </contact>
    <investigator>
      <last_name>Laurent CANY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier SAINT-JEAN de PERPIGNAN</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Faiza KHEMISSA, Dr</last_name>
      <phone>+33 4 68 61 61 37</phone>
      <email>faiza.khemissa@ch-perpignan.fr</email>
    </contact>
    <investigator>
      <last_name>Faiza KHEMISSA, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Poitiers - La Miletrie</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>DAVID TOUGERON, Pr</last_name>
      <phone>+33 5 49 44 37 51</phone>
      <email>david.tougeron@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>DAVID TOUGERON, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Robert Debre</name>
      <address>
        <city>Reims CEDEX</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Olivier BOUCHE, Pr</last_name>
      <phone>+33 3 26 78 71 72</phone>
      <email>obouche@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier BOUCHE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51726</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Damien BOTSEN, C</last_name>
      <phone>+33 3 26 78 71 70</phone>
      <email>damien.botsen@reims.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Damien BOTSEN, BOTSEN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Pontchaillou - Rennes</name>
      <address>
        <city>Rennes CEDEX 9</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Astrid LIEVRE, Pr</last_name>
      <phone>+33 2 99 28 99 72</phone>
      <email>astrid.lievre@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Astrid LIEVRE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Drome Nord</name>
      <address>
        <city>Romans-sur-Isère</city>
        <zip>26100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie-Claude GOUTTEBEL, Dr</last_name>
      <phone>+33 4 75 05 76 59</phone>
      <email>mc.gouttebel@hopitaux-drome-nord.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Claude GOUTTEBEL, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ico - Site René Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Judith RAIMBOURG, Dr</last_name>
      <phone>+33 2 40 67 98 21</phone>
      <email>judith.raimbourg@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Judith RAIMBOURG, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de St Malo</name>
      <address>
        <city>Saint-Malo</city>
        <zip>35403</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anaïs BODERE, Dr</last_name>
      <phone>+33 2 99 21 22 64</phone>
      <email>anais.bodere@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Anaïs BODERE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Saint Etienne-Hopital Nord - Service Hge</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-Marc PHELIP, Pr</last_name>
      <phone>+33 4 77 82 86 19</phone>
      <email>j.marc.phelip@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Marc PHELIP, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique Saint Claude</name>
      <address>
        <city>Saint-Quentin</city>
        <zip>02100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre VANELSLANDER, Dr</last_name>
      <email>vanelspi@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Charcot - Sainte Foy Les Lyon</name>
      <address>
        <city>Sainte-Foy-lès-Lyon</city>
        <zip>69510</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Clémence THEVENET, Dr</last_name>
      <phone>+33 4 72 32 30 13</phone>
      <email>clemence.thevenet@endolyonso.com</email>
    </contact>
    <investigator>
      <last_name>Clémence THEVENET, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte Anne</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Louis-Marie DOURTHE, Dr</last_name>
      <phone>+33 3 88 45 37 50</phone>
      <email>lm.dourthe@solcrr.org</email>
    </contact>
    <investigator>
      <last_name>Louis-Marie DOURTHE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CAC - Paul Strauss / ICAN STRASBOURG</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Meher BEN ABDELGHANI, Dr</last_name>
      <phone>+33 3 88 25 24 85</phone>
      <email>mbenabdelghani@strasbourg.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Meher BEN ABDELGHANI, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HAUTEPIERRE CHU de STRASBOURG</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marlène TAMBOU-NGUIMPI, Dr</last_name>
      <phone>+33 3 88 12 74 54</phone>
      <email>marlene.nguimpidjatsa@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Marlène TAMBOU-NGUIMPI, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>May MABRO, Dr</last_name>
      <phone>+33 1 46 25 28 64</phone>
      <email>m.mabro@hopital-foch.org</email>
    </contact>
    <investigator>
      <last_name>May MABRO, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique de L'Ormeau</name>
      <address>
        <city>Tarbes</city>
        <zip>65000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Philippe AYELA, Dr</last_name>
      <phone>+33 5 62 93 59 29</phone>
      <email>nathaliemonteiro@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe AYELA, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Sainte Musse</name>
      <address>
        <city>Toulon</city>
        <zip>83000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Camille SIBERTIN-BLANC, Dr</last_name>
      <phone>+33 4 94 14 52 75</phone>
      <email>camille.sibertin-blanc@ch-toulon.fr</email>
    </contact>
    <investigator>
      <last_name>Camille SIBERTIN-BLANC, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU TROUSSEAU de TOURS</name>
      <address>
        <city>Tours CEDEX 9</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Thierry LECOMTE, Pr</last_name>
      <phone>+33 2 47 47 59 00</phone>
      <email>thierry.lecomte@med.univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry LECOMTE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CENTRE HOSPITALIER de VALENCIENNES</name>
      <address>
        <city>Valenciennes</city>
        <zip>59300</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Eduardo BARRASCOUT</last_name>
      <phone>+33 3 27 14 32 05</phone>
      <email>barrascout-e@ch-valenciennes.fr</email>
    </contact>
    <investigator>
      <last_name>Eduardo BARRASCOUT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre LEHAIR, Dr</last_name>
      <phone>+33 3 83 59 83 65</phone>
      <email>p.lehair@nancy.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre LEHAIR, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Ayhan ULUSAKARYA, Dr</last_name>
      <phone>+33 1 45 59 35 70</phone>
      <email>ayhan.ulusakarya@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Ayhan ULUSAKARYA, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Carbonnel F, Soularue E, Coutzac C, Chaput N, Mateus C, Lepage P, Robert C. Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora? Semin Immunopathol. 2017 Apr;39(3):327-331. doi: 10.1007/s00281-016-0613-x. Epub 2017 Jan 16. Review.</citation>
    <PMID>28093620</PMID>
  </reference>
  <reference>
    <citation>Caulet M, Lecomte T, Bouché O, Rollin J, Gouilleux-Gruart V, Azzopardi N, Léger J, Borg C, Douillard JY, Manfredi S, Smith D, Capitain O, Ferru A, Moussata D, Terrebone E, Paintaud G, Ternant D. Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients. Clin Pharmacokinet. 2016 Nov;55(11):1381-1394.</citation>
    <PMID>27312193</PMID>
  </reference>
  <reference>
    <citation>Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012 Jun 28;486(7404):537-40. doi: 10.1038/nature11219.</citation>
    <PMID>22722843</PMID>
  </reference>
  <reference>
    <citation>Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012 Mar 15;12(4):298-306. doi: 10.1038/nrc3245. Review.</citation>
    <PMID>22419253</PMID>
  </reference>
  <reference>
    <citation>Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018 Jan 5;359(6371):97-103. doi: 10.1126/science.aan4236. Epub 2017 Nov 2.</citation>
    <PMID>29097493</PMID>
  </reference>
  <reference>
    <citation>Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001 Feb 1;19(3):843-50.</citation>
    <PMID>11157038</PMID>
  </reference>
  <reference>
    <citation>Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011.</citation>
    <PMID>25428504</PMID>
  </reference>
  <reference>
    <citation>Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, Adamow M, Kuk D, Panageas KS, Carrera C, Wong P, Quagliarello F, Wubbenhorst B, D'Andrea K, Pauken KE, Herati RS, Staupe RP, Schenkel JM, McGettigan S, Kothari S, George SM, Vonderheide RH, Amaravadi RK, Karakousis GC, Schuchter LM, Xu X, Nathanson KL, Wolchok JD, Gangadhar TC, Wherry EJ. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017 May 4;545(7652):60-65. doi: 10.1038/nature22079. Epub 2017 Apr 10.</citation>
    <PMID>28397821</PMID>
  </reference>
  <reference>
    <citation>Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, Konieczny BT, Daugherty CZ, Koenig L, Yu K, Sica GL, Sharpe AH, Freeman GJ, Blazar BR, Turka LA, Owonikoko TK, Pillai RN, Ramalingam SS, Araki K, Ahmed R. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science. 2017 Mar 31;355(6332):1423-1427. doi: 10.1126/science.aaf0683. Epub 2017 Mar 9.</citation>
    <PMID>28280249</PMID>
  </reference>
  <reference>
    <citation>Lamas B, Richard ML, Leducq V, Pham HP, Michel ML, Da Costa G, Bridonneau C, Jegou S, Hoffmann TW, Natividad JM, Brot L, Taleb S, Couturier-Maillard A, Nion-Larmurier I, Merabtene F, Seksik P, Bourrier A, Cosnes J, Ryffel B, Beaugerie L, Launay JM, Langella P, Xavier RJ, Sokol H. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med. 2016 Jun;22(6):598-605. doi: 10.1038/nm.4102. Epub 2016 May 9.</citation>
    <PMID>27158904</PMID>
  </reference>
  <reference>
    <citation>Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012 Jun 28;486(7404):532-6. doi: 10.1038/nature11156.</citation>
    <PMID>22722830</PMID>
  </reference>
  <reference>
    <citation>Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015 Apr;36(4):265-76. doi: 10.1016/j.it.2015.02.008. Epub 2015 Mar 18. Review.</citation>
    <PMID>25797516</PMID>
  </reference>
  <reference>
    <citation>Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J; MetaHIT Consortium, Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010 Mar 4;464(7285):59-65. doi: 10.1038/nature08821.</citation>
    <PMID>20203603</PMID>
  </reference>
  <reference>
    <citation>Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.</citation>
    <PMID>29097494</PMID>
  </reference>
  <reference>
    <citation>Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011 Jun;11(6):426-37. doi: 10.1038/nrc3066. Epub 2011 May 12. Review.</citation>
    <PMID>21562580</PMID>
  </reference>
  <reference>
    <citation>Sokol H, Leducq V, Aschard H, Pham HP, Jegou S, Landman C, Cohen D, Liguori G, Bourrier A, Nion-Larmurier I, Cosnes J, Seksik P, Langella P, Skurnik D, Richard ML, Beaugerie L. Fungal microbiota dysbiosis in IBD. Gut. 2017 Jun;66(6):1039-1048. doi: 10.1136/gutjnl-2015-310746. Epub 2016 Feb 3.</citation>
    <PMID>26843508</PMID>
  </reference>
  <reference>
    <citation>Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta. 2001 Nov;313(1-2):139-42.</citation>
    <PMID>11694251</PMID>
  </reference>
  <reference>
    <citation>Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, Gillet B, Gongora C, Dechelotte P, Robert B, Del Rio M, Lamy PJ, Bibeau F, Nouaille M, Loriot V, Jarrousse AS, Molina F, Mathonnet M, Pezet D, Ychou M. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014 Apr;20(4):430-5. doi: 10.1038/nm.3511. Epub 2014 Mar 23.</citation>
    <PMID>24658074</PMID>
  </reference>
  <reference>
    <citation>Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014 Nov 27;515(7528):568-71. doi: 10.1038/nature13954.</citation>
    <PMID>25428505</PMID>
  </reference>
  <reference>
    <citation>Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ, Schlitzer A, Ginhoux F, Apetoh L, Chachaty E, Woerther PL, Eberl G, Bérard M, Ecobichon C, Clermont D, Bizet C, Gaboriau-Routhiau V, Cerf-Bensussan N, Opolon P, Yessaad N, Vivier E, Ryffel B, Elson CO, Doré J, Kroemer G, Lepage P, Boneca IG, Ghiringhelli F, Zitvogel L. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013 Nov 22;342(6161):971-6. doi: 10.1126/science.1240537.</citation>
    <PMID>24264990</PMID>
  </reference>
  <reference>
    <citation>Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013 Mar 29;339(6127):1546-58. doi: 10.1126/science.1235122. Review.</citation>
    <PMID>23539594</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 6, 2020</study_first_submitted>
  <study_first_submitted_qc>February 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2020</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunotherapy</keyword>
  <keyword>immune infiltrate</keyword>
  <keyword>first line</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

